bpc-157 original The Hidden Risks of BPC‑157: What Patients Need to Know About Contamination and Safety BPC-157: Experimental Peptide Creates Risk

In diet-induced obese mice, studied for reductions in body weight, fat mass, and adipocyte size without altering food intake

A cold pack or wrapped ice to apply briefly after the shot

Pre-existing inborn errors of sulfur-amino-acid metabolism (e.g., homocystinuria) represent an absolute contraindication because parenteral methionine can exacerbate elevated homocysteine concentrations and associated thrombotic risk

Some patients are trained to self-inject after the first few doses at the clinic

Peptide origin / Partial sequence of human gastric protein BPC, isolated from gastric juice Molecular weight / Approximately 1,419 Da (15 amino acids) Common off-label oral dose / 250 to 500 mcg twice daily, taken on an empty stomach Common off-label subcutaneous dose / 200 to 300 mcg once or twice daily near the affected area or abdominally Evidence level / Preclinical only (GRADE: very low certainty for human GI healing) Key preclinical finding / Accelerated gastric ulcer healing in rats within 24 to 72 hours across multiple models Route preference for GI targets / Oral administration, based on topical mucosal contact rationale Safety profile in humans / Largely unknown